# Beita Pharmatech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beita-pharmatech

- Industry: Pharmaceuticals
- Headquarters: Jiangyin, China
- Website: www.beitapharmatech.com
- Latest round: Series B (Mar 20, 2021)
- Investors on record: 2

## About

Established in 2008, and based in Wuxi, China, Beita Pharmatech is a healthcare company that focuses on the development of isotopically labeled precursor compounds. It has obtained 16 patents and published 8 academic papers as of 2022. It has partnerships with the China Institute of Nuclear Power Research and Design, China Academy of Atomic Energy Research, China Academy of Engineering Physics, RC TRITEC and Cambridge Isotope Laboratories, Inc. It has a subsidiary Changsha Beita Pharmatech Co., Ltd. In April 2023, Beita Pharmatech raised strategic investment from new investor Haide Huijin Venture Investment.

Its products can be divided into radioisotope labeled products, and stable isotope labeled products. The radioisotope labeled products include BTR-1 C-14 BaCO3, BTR-2 Urea-14C, and BTR-Pre C-14 labeled precursors. The stable isotope labeled products include BTS-1 C-13 BaCO3, and BTS-2 Urea-13C. It enables labelled for pharmaceuticals, pesticides, small molecules or bioactive molecules.

## Funding rounds

- Series B, Mar 20, 2021 — Fortune Link
- Series A, Apr 8, 2014 — Kaiwu Capital

## Investors

- Kaiwu Capital (https://capitalatlas.ai/funds/kaiwu-capital) — Series A
- Fortune Link (https://capitalatlas.ai/funds/fortune-link) — Series B